4.3 Article

Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery

期刊

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
卷 68, 期 5, 页码 735-745

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00228-011-1206-1

关键词

Cefoxitin; Prophylaxis; Surgery; Population pharmacokinetics

资金

  1. Caja Vital Kutxa
  2. Departamento de Educacion, Universidades e Investigacion, Gobierno Vasco, Spain [IT341-10]
  3. Departamento de Sanidad, Gobierno Vasco, Spain

向作者/读者索取更多资源

To elucidate whether a dose of 2 g cefoxitin as a prophylactic agent in patients undergoing elective colorectal surgery is able to maintain free drug concentrations above the minimum inhibitory concentration of the microorganisms involved in surgical site infection. This was a prospective study involving 56 patients electively undergoing rectal or colon surgery. All plasma concentration-time data were analyzed simultaneously using the population approach to estimate population pharmacokinetic parameters and study the influence of the subjects' demographic characteristics, disease status, surgical procedure, and clinical laboratory values on the pharmacokinetic properties of cefoxitin. A one-compartment open model was chosen to describe plasma concentrations of cefoxitin. Since cefoxitin is eliminated almost entirely via the kidney, creatinine clearance was identified as a covariate of cefoxitin clearance. The relationship between total cefoxitin clearance (CL) and creatinine clearance (CLCR) was best described using a nonlinear model [CL = 11.5 x (CLCR/77)(0.52)]. The population apparent volume of distribution was 12 L. Computer simulations carried out to determine the probability to maintain free plasma concentrations above 8 mg/L (the concentration threshold for susceptible bacteria) 2 h after drug administration revealed that this probability decreased from 84% in patients with a CLCR of 40 mL/min to 28% in patients with a CLCR of 100 mL/min. To ensure cefoxitin target concentrations during surgery, we recommend that cefoxitin be administered every 1.5 h in patients with a CLCR a parts per thousand yen60 mL/min and every hour if the CLCR is a parts per thousand yen100 mL/min. Administration by continuous infusion preceded by a bolus injection should also be considered.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据